Sanofi Reports final analysis Data for Tepotinib in Psoriatic arthritis

Sanofi today announced final analysis results for Tepotinib in patients with Psoriatic arthritis. The study demonstrated that Tepotinib provides durable benefit over long-term follow-up compared to standard of care or placebo. These results provide important insights into the treatment of Psoriatic arthritis and support the continued development of Tepotinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Tepotinib was consistent with previous observations, with no new safety signals identified.